Compare LAD & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAD | COGT |
|---|---|---|
| Founded | 1946 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 6.0B |
| IPO Year | 1996 | 2018 |
| Metric | LAD | COGT |
|---|---|---|
| Price | $287.82 | $31.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 15 |
| Target Price | ★ $361.89 | $36.21 |
| AVG Volume (30 Days) | 257.2K | ★ 1.9M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.76% | N/A |
| EPS Growth | ★ 9.01 | N/A |
| EPS | ★ 4.28 | N/A |
| Revenue | ★ $11,821,400,000.00 | $7,871,000.00 |
| Revenue This Year | $4.06 | N/A |
| Revenue Next Year | $4.18 | $1,733.58 |
| P/E Ratio | $67.89 | ★ N/A |
| Revenue Growth | ★ 17.20 | N/A |
| 52 Week Low | $239.78 | $6.59 |
| 52 Week High | $360.56 | $43.73 |
| Indicator | LAD | COGT |
|---|---|---|
| Relative Strength Index (RSI) | 52.22 | 35.88 |
| Support Level | $269.00 | $30.87 |
| Resistance Level | $292.05 | $37.69 |
| Average True Range (ATR) | 8.64 | 1.50 |
| MACD | 0.81 | -0.11 |
| Stochastic Oscillator | 71.17 | 3.94 |
Lithia Motors is a retailer of new and used vehicles and related services. The company offers nearly 60 brands of vehicles at nearly 500 stores globally across the US, Canada, and UK. The company has expanded largely through the acquisition of dealerships in smaller regional markets but now seeks to grow in any part of the US and we expect more deals over time in the US and, at times, abroad. Annual revenue in 2025 was $37.6 billion and we see over $50 billion possible in a few years. The US was 78.5% of 2025 revenue and the UK second at 18.4%, due to the 2024 Pendragon acquisition. In 2025, new vehicle sales were about 50% of total revenue. Lithia was founded in 1946, went public in 1996, and is the largest US auto dealer. It is based in Medford, Oregon.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.